PSA levels within 2 years of diagnosis do not predict lethal prostate cancer outcomes

被引：0
|
作者：
机构：
来源：
Nature Clinical Practice Urology | 2007年 / 4卷 / 7期
关键词：
D O I：
10.1038/ncpuro0825
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：351 / 352
页数：1
相关论文
共 50 条
  • [41] Dynamic changes in PSA levels predict prognostic outcomes in prostate cancer patients undergoing androgen -deprivation therapy: A multicenter retrospective analysis
    Hu, Mingqiu
    Mao, Yifeng
    Guan, Chao
    Tang, Zhizhong
    Bao, Zhihang
    Li, Yingbang
    Liang, Guowu
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [42] PROSTATE-SPECIFIC ANTIGEN (PSA) LEVELS IN MEN AGED 60 TO 70 AND DEVELOPMENT OF LETHAL PROSTATE CANCER OVER 30 YEARS: IMPLICATIONS FOR RISK-STRATIFIED SCREENING
    Preston, Mark
    Downer, Mary Kathryn
    Gerke, Travis
    Carlsson, Sigrid
    Sesso, Howard
    Kibel, Adam
    Trinh, Quoc-Dien
    Lilja, Hans
    Vickers, Andrew
    Wilson, Kathryn
    Mucci, Lorelei
    JOURNAL OF UROLOGY, 2017, 197 (04): : E487 - E488
  • [43] Testing a multigene model to predict lethal prostate cancer
    Rubin, M. A.
    Mucci, L. A.
    Pawilan, Y.
    Demichelis, F.
    Fall, K.
    Stark, J. R.
    Adami, H-O
    Andersson, S-O
    Andren, O.
    Holmberg, L.
    Huang, W.
    Kanloff, P. W.
    Kim, R.
    Pernet, S.
    Stampfer, M. J.
    Johansson, J-F
    MODERN PATHOLOGY, 2008, 21 : 178A - 179A
  • [44] Testing a multigene model to predict lethal prostate cancer
    Rubin, M. A.
    Mucci, L. A.
    Pawitan, Y.
    Demichelis, F.
    Fall, K.
    Stark, J. R.
    Adami, H-O
    Anderson, S-O
    Andren, O.
    Holmberg, L.
    Huang, W.
    Kantoff, P. W.
    Kim, R.
    Perner, S.
    Stampfer, M. J.
    Johansson, J-E
    LABORATORY INVESTIGATION, 2008, 88 : 178A - 179A
  • [45] BASELINE PSA LEVELS IN MIDLIFE & FUTURE DEVELOPMENT OF LETHAL PROSTATE CANCER: A DIVERSE NORTH AMERICAN COHORT ANALYSIS
    Davis, Matthew
    Stephens, Alexander
    Morrison, Chase
    Majdalany, Sami
    Affas, Rafe
    Arora, Sohrab
    Corsi, Nicholas
    Rakic, Ivan
    Sood, Akshay
    Rogers, Craig
    Abdollah, Firas
    JOURNAL OF UROLOGY, 2023, 209 : E545 - E545
  • [46] Baseline PSA levels in midlife & future development of lethal prostate cancer: A diverse North American cohort analysis
    Davis, M.
    Stephens, A.
    Morrison, C.
    Majdalany, S.
    Affas, R.
    Arora, S.
    Corsi, N.
    Rakic, I
    Sood, A.
    Rogers, C.
    Abdollah, F.
    EUROPEAN UROLOGY, 2023, 83 : S367 - S367
  • [47] HOW DO PSA-BASED MARKERS PREDICT CLINICALLY SIGNIFICANT PROSTATE CANCER (CSPCA) ON PROSTATE BIOPSY INDEPENDENT OF PROSTATE SIZE
    Kuster, Max
    Ou, Michelle
    Gaines, Jacob
    Macdonald, Eric
    Hall, Simon
    JOURNAL OF UROLOGY, 2022, 207 (05): : E899 - E900
  • [48] PSA Nadir 2 Years after Definitive SBRT for Prostate Cancer: Predictors of Absolute PSA Decline
    Blacksburg, S. R.
    Sheu, R.
    Demircioglu, G.
    Mirza, A.
    Carpenter, T. J.
    Morgenstern, J.
    Witten, M. R.
    Mendez, C.
    Endres, P.
    Katz, A. E.
    Haas, J. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E100 - E100
  • [49] Biparametric prostate MRI and clinical indicators predict clinically significant prostate cancer in men with "gray zone" PSA levels
    Wei, Chao-gang
    Chen, Tong
    Zhang, Yue-yue
    Pan, Peng
    Dai, Guang-cheng
    Yu, Hong-chang
    Yang, Shuo
    Jiang, Zhen
    Tu, Jian
    Lu, Zhi-hua
    Shen, Jun-kang
    Zhao, Wen-lu
    EUROPEAN JOURNAL OF RADIOLOGY, 2020, 127
  • [50] PROSTATE HEALTH INDEX AND %P2PSA PREDICT FINAL PATHOLOGICAL OUTCOMES IN ITALIAN PATIENTS UNDERGOING RADICAL PROSTATECTOMY FOR PROSTATE CANCER
    De Luca, Stefano
    Passera, Roberto
    Bollito, Enrico
    Sottile, Antonino
    Manfredi, Matteo
    Mele, Fabrizio
    Poggio, Massimiliano
    Grande, Susanna
    Garrou, Diletta
    Aimar, Roberta
    Fiori, Cristian
    Porpiglia, Francesco
    ANTICANCER RESEARCH, 2015, 35 (06) : 3725 - 3726
12345